|EMP2 regulates angiogenesis in endometrial cancer cells through induction of VEGF.|
|Jump to Full Text|
|PMID: 23334331 Owner: NLM Status: MEDLINE|
|Understanding tumor-induced angiogenesis is a challenging problem with important consequences for the diagnosis and treatment of cancer. In this study, we define a novel function for epithelial membrane protein-2 (EMP2) in the control of angiogenesis. EMP2 functions as an oncogene in endometrial cancer, and its expression has been linked to decreased survival. Using endometrial cancer xenografts, modulation of EMP2 expression resulted in profound changes to the tumor microvasculature. Under hypoxic conditions, upregulation of EMP2 promoted vascular endothelial growth factors (VEGF) expression through a HIF-1α-dependent pathway and resulted in successful capillary-like tube formation. In contrast, reduction of EMP2 correlated with reduced HIF-1α and VEGF expression with the net consequence of poorly vascularized tumors in vivo. We have previously shown that targeting of EMP2 using diabodies in endometrial cancer resulted in a reduction of tumor load, and since then we have constructed a fully human EMP2 IgG1. Treatment of endometrial cancer cells with EMP2-IgG1 reduced tumor load with a significant improvement in survival. These results support the role of EMP2 in the control of the tumor microenvironment and confirm the cytotoxic effects observed by EMP2 treatment in vivo.|
|L K Gordon; M Kiyohara; M Fu; J Braun; P Dhawan; A Chan; L Goodglick; M Wadehra|
|Type: Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't Date: 2013-01-21|
|Title: Oncogene Volume: 32 ISSN: 1476-5594 ISO Abbreviation: Oncogene Publication Date: 2013 Nov|
|Created Date: 2013-11-14 Completed Date: 2014-01-15 Revised Date: 2014-03-28|
Medline Journal Info:
|Nlm Unique ID: 8711562 Medline TA: Oncogene Country: England|
|Languages: eng Pagination: 5369-76 Citation Subset: IM|
|APA/MLA Format Download EndNote Download BibTex|
Cell Line, Tumor
Endometrial Neoplasms / blood supply*, metabolism
Immunoglobulin G / immunology
Membrane Glycoproteins / immunology, physiology*
Vascular Endothelial Growth Factor A / biosynthesis*
|CA-86366/CA/NCI NIH HHS; CA131756/CA/NCI NIH HHS; CA16042/CA/NCI NIH HHS; CA163971/CA/NCI NIH HHS; P30 CA016042/CA/NCI NIH HHS; R01 CA163971/CA/NCI NIH HHS; R21 CA131756/CA/NCI NIH HHS|
|0/EMP2 protein, human; 0/Immunoglobulin G; 0/Membrane Glycoproteins; 0/Vascular Endothelial Growth Factor A|
Journal ID (nlm-ta): Oncogene
Journal ID (iso-abbrev): Oncogene
Publisher: Nature Publishing Group
Copyright © 2013 Macmillan Publishers Limited
Received Day: 21 Month: 02 Year: 2012
Revision Received Day: 19 Month: 10 Year: 2012
Accepted Day: 02 Month: 11 Year: 2012
Print publication date: Day: 14 Month: 11 Year: 2013
Electronic publication date: Day: 21 Month: 01 Year: 2013
Volume: 32 Issue: 46
First Page: 5369 Last Page: 5376
PubMed Id: 23334331
Publisher Item Identifier: onc2012622
|EMP2 regulates angiogenesis in endometrial cancer cells through induction of VEGF Alternate Title:EMP2 regulates tumor neoangiogenesis|
|L K Gordon1|
1Department of Ophthalmology, David Geffen School of Medicine at UCLA, Los Angeles, CA, USA
2Department of Pathology and Laboratory Medicine, David Geffen School of Medicine at UCLA, Los Angeles, CA, USA
3Jonsson Comprehensive Cancer Center, David Geffen School of Medicine at UCLA, Los Angeles, CA, USA
4Department of Surgery, Harbor UCLA Medical Center, Torrance, CA, USA
|*Department of Pathology and Laboratory Medicine, David Geffen School of Medicine at UCLA, Los Angeles, CA 90095, USA. Email: firstname.lastname@example.org
Sprouting angiogenesis—the process by which new blood vessels grow from existing ones—is a ubiquitous phenomenon in health and disease. It has a pivotal role in diverse processes from embryo development to wound healing to tumor growth.1 Regarding tumor angiogenesis, it has been shown that solid tumor growth depends on successful neovascularization and several factors, the most notable being vascular endothelial growth factors (VEGFs), have been shown to promote tumor angiogenesis. VEGFs were first described as a potent vascular permeability factor (VPF) secreted by tumor cells that stimulate a rapid and reversible increase in microvascular permeability without mast cell degranulation or endothelial cell damage.2 Its importance in tumor biology has led to the development of several drugs, the most notable being the recently FDA-approved bevacizumab (Avastin; Genentech, San Francisco, CA, USA)—a humanized anti-VEGF antibody, as anticancer agents.3, 4
VEGF polypeptides belong to the PDGF family of growth factors, and are perhaps the most important players that regulate vessel formation.3 VEGFs are encoded by a family of genes that includes VEGF-A, -B, -C, -D and placental growth factor.5 They are dimeric cysteine-linked secreted glycoproteins with a molecular weight of ∼40 kDa. Produced in response to hypoxia, specific growth and differentiation factors, and by oncogenes, VEGFs are produced by many cell types, including tumor cells.5, 6 In tumors, VEGF-A appears to be most potent angiogenic of the vascular growth factors,7 and its secretion has been shown to be critical for tumor growth.3, 7 Thus, understanding the mechanisms that control angiogenesis, and in particular that control VEGF-A expression, are of paramount importance in tumor biology.
Epithelial membrane protein-2 (EMP2) is a tetraspan protein of the GAS-3/PMP22 family. Concordant with the role of tetraspans, EMP2 is thought to curate molecules on the plasma membrane to regulate the activity of specific signaling complexes. EMP2 coordinates the activity of select integrin isoforms, coalescing in the activation of FAK and Src.8, 9, 10 Recently, EMP2 has also been revealed as a novel oncogene upregulated in a number of tumors including endometrial,11 ovarian12 and gliomas.13 Upregulation of EMP2 expression has been associated with tumor progression, invasion and poor patient prognosis.11, 14
To date, the mechanism of how changes in EMP2 levels affect the tumor microenvironment has not been evaluated. Using a model for endometrial cancer, we determined that an important function of EMP2 is as a regulator of angiogenesis. We demonstrate that increased EMP2 promotes endothelial cell tube formation through increased VEGF-A expression. Therapeutic targeting of EMP2 using monoclonal antibodies reduces tumor vasculature, identifying a novel mechanism of reducing tumor load through indirect control of VEGF-A.
We have previously shown that anti-EMP2 diabodies reduce tumor load in HEC1A xenografts.15 Since this original study, a recombinant EMP2 IgG1 antibody has been designed and shown to be therapeutically beneficial in mouse models of breast cancer (Fu and Wadehra, submitted). To determine the efficacy of EMP2 IgG1 for endometrial cancer, subcutaneous xenografts using the HEC1A/EMP2 cell line were created. Systemic weekly injections of EMP2 IgG1 reduced tumor load compared to control IgG (Figure 1a). This reduction in tumor load translated into a significant increase in survival for mice treated with EMP2 IgG1 (Figure 1b; P=0.02). Even after 84 days, surviving mice showed no measurable change in tumor size. Upon histologic examination, central necrosis was prominent in the tumors after anti-EMP2 antibody treatment compared with the control (Figure 1c). Although this can be attributed partially to higher interstitial pressure and poorer blood flow at the center of tumors,16, 17 significantly less necrosis was visible in tumors with control IgG antibodies treatment. To analyze these alterations in tumor vasculature, immunostaining for vasculature was performed using Lycopersicon esculentum lectin on surviving clusters of tumor cells. Lectin immunostaining studies confirmed the marked loss of vessels during anti-EMP2 treatment in areas of viable tumor (1D).
To further examine whether the reductions in tumor vascularity from EMP2 treatment were due to vessel regression or reduced angiogenesis, tumors were stained with Masson's trichrome to detect the presence of collagen sleeves18, 19 in necrotic areas (Figure 1e). All treatment groups had scattered fragments of basement membrane (Figure 1e, arrowheads), but empty basement membrane sleeves were more abundant in areas of necrosis after the anti-EMP2 antibody than control treatments. This suggests that blockade of EMP2 is a novel mechanism to reduce tumor neovascularization.
Recent studies have shown that EMP2 expression is upregulated in endometrial tumors and that its expression alters tumor cell development.11, 14 Studies have also shown that modulation of EMP2 does not significantly alter tumor cell proliferation.9 Therefore, we postulated that it may be an important regulator of the tumor cell microenvironment. To test this idea, tumors were created from endometrial cancer cells that overexpressed EMP2 (HEC1A/EMP2), expressed a vector control (HEC1A/V) or expressed a ribozyme to reduce its levels (HEC1A/RIBO). Masson's trichrome staining of xenografts suggested that EMP2 expression altered tumor vasculature (Figure 2a). HEC1A/EMP2 tumors were highly vascularized, whereas tumors with reduced EMP2 (HEC1A/RIBO) levels formed small tumors with poor vasculature and large areas of necrosis.
To confirm that EMP2 levels correlated with increased numbers of blood vessels, tumors were stained with L. esculentum lectin, which binds uniformly to the luminal surface of the endothelium,20 and DAPI. HEC1A/EMP2 tumors showed increased tumor-associated vasculature compared with the HEC1A/V tumors. Similar staining of HEC1A/RIBO tumors showed poor tumor vasculature with some background staining in the areas of necrosis (Figure 2b). Xenografts were also stained with CD34 antibodies (Figure 2c). Concordantly, quantitation of staining revealed a significant correlation between EMP2 expression and CD34+ cells (Figure 2d).
We used several approaches to investigate whether and how EMP2 could regulate the behavior of endothelial cells. Initially, the chemotactic response of human umbilical vein endothelial cells (HUVECs) to supernatants from EMP2-modified cell lines was tested using Boyden chambers. Conditioned media was collected from cells grown under hypoxic conditions for up to 24 h. Conditioned media from cells that overexpressed EMP2 significantly enhanced directional migration compared to control cells (P=0.04; Figure 3a). Reduction in EMP2 expression further reduced cell migration by two-fold over control cells (P=0.03). To confirm that EMP2 expression altered endothelial cell migration, a ‘scratch' test was performed on a confluent monolayer of HUVEC cells. Concordant with the previous results, an EMP2 dose-dependent response was also observed using conditional medium from hypoxic HEC1A/EMP2, HEC1A/V or HEC1A/RIBO cells (Figure 3b). No statistically significant differences were observed from conditioned media collected from normoxic cells (data not shown).
To determine whether EMP2 altered the functional behavior of endothelial cells, HUVEC cells were placed on a basement membrane matrix to induce capillary-like tube formation.21 Cells were incubated in hypoxic cultured supernatants from HEC1A/EMP2, HEC1A/V and HEC1A/RIBO (Figure 3c). An EMP2-dependent response was observed in capillary-like tube formation, as HEC1A/EMP2 induced more tube formation and tubes with a greater diameter than HEC1A/V (Figures 3d and e). Reduction in EMP2 expression in HEC1A cells further reduced the number of tubes formed compared with HEC1A/V, suggesting that EMP2 expression is necessary for endometrial tumor angiogenesis. This effect was also observed when EMP2 levels were reduced using shRNA, and although a similar trend in capillary-like tube formation was observed from normoxic cultured supernatants between HEC1A/EMP2 and HEC1A/V, these results were not statistically significant (data not shown). No significant difference in HUVEC cell proliferation was observed within the experimental window (data not shown).
The reduction in vessel formation in HEC1A/RIBO and HEC1A/sh911 suggested that EMP2 in part regulated the tumor microenvironment via new blood vessel formation. In order to link anti-EMP2 treatment with changes in neovascularization, we initially treated HEC1A/EMP2 cells for 12–15 h under hypoxic conditions with anti-EMP2 IgG1 or control antibodies to determine their effect on capillary-like HUVEC tube formation, as no cellular toxicity was visible at this early time point. EMP2 IgG1 treatment was sufficient to reduce HUVEC tube formation in vitro in a dose-dependent manner (Figure 3f).
To determine if the effects of EMP2 on endothelial cells are cell type specific, similar experiments were performed on primary human aortic endothelial cells (HAEC). Using supernatant from hypoxic HEC1A/EMP2, HEC1A/V or HEC1A/RIBO as a chemoattractant, Boyden chamber assays were performed on HAEC. Similar to results using HUVEC cultures, tumor expression of EMP2 promoted HAEC invasion (Figure 4a). These combined results suggest that EMP2 upregulation leads to an increase in proangiogenic events. Several cellular and molecular changes have been shown to promote tumor angiogenesis,22 with the most potent inducer being VEGF.23 In order to determine if VEGF contributed to HAEC invasion, tumor cell supernatants were incubated with bevacizumab, a monoclonal antibody to VEGF. Treatment with bevacizumab reduced HAEC migration to control levels, suggesting that EMP2 may regulate VEGF expression (Figure 4a).
In order to determine if EMP2 expression altered VEGF expression and secretion, cells were grown in normoxia or placed in a hypoxic chamber for 24 h. VEGF expression was below detection under normoxic conditions. However, when cells were placed in hypoxia, EMP2 expression directly correlated with total VEGF protein levels (Figure 4b) as well as with secreted VEGF (Figure 4c). In contrast, reduction of EMP2 resulted in undetectable levels of VEGF by western blot and low levels of secreted protein. To confirm these results, semi-quantitative RT-PCR was performed on hypoxic HEC1A/EMP2, HEC1A/V and HEC1A/RIBO cells. VEGF-A exists as multiple isoforms, which are generically referred to as VEGFxxx and result from the pre-mRNA alternative splicing of eight exons.24 Alternative splicing of VEGF-A was initially shown to generate four different isoforms with 121, 165, 189 and 206 amino acids (VEGF121, VEGF165, VEGF189, VEGF206, respectively25). EMP2 levels directly increased the mRNA expression of several VEGF isoforms (VEGF165 and VEGF121), whereas a reduction in EMP2 produced reduced VEGF expression (Figure 4d). Low levels of VEGF189 mRNA was observed in HEC1A/EMP2 cells, and no expression of VEGF206 was detected in any of the cell lines.
In the previous experiments, we demonstrated that downregulation of EMP2 in the tumor cell reduced capillary formation, and the motility of endothelial cells using coculture assays. This may be the result of reduced VEGF secretion by these cells or due to the expression of anti-angiogenic agents. To address this question, varying amounts of VEGF were added to the supernatants from vehicle control or cells with reduced EMP2 levels (HEC1A/RIBO or HEC1A/sh911). Exogenous VEGF was sufficient to induce HUVEC cell tube formation (Figure 4e), suggesting that the absence of VEGF contributed to the lack of tube formation.
Several oncogenic as well as growth factor-driven pathways have been shown to regulate VEGF expression. As hypoxic conditions have been shown to trigger many oncogenic signaling pathways,26 we initially investigated if the levels of EMP2 were sufficient to alter the expression of hypoxia-induced transcription factors (HIF), specifically HIF-1α and HIF-2α. In all EMP2 HEC1A variants, no expression of HIF-2α was observed (data not shown). However, the expression of HIF-1α correlated with EMP2 expression. The highest levels of HIF-1α directly correlated with the highest concentration of EMP2 expression under hypoxic conditions (Figure 5a). Reciprocally, HEC1A/RIBO cells produced below detection levels of HIF-1α under the same conditions. To confirm that lower levels of EMP2 reduce HIF-1α expression, shRNA constructs were generated to express a vehicle control or reduce EMP2 expression (Figure 5a, right). Similar to the ribozyme, HEC1A/sh911 showed reduced HIF-1α expression compared to the vehicle control (HEC1A/shCtrl). To quantitate the difference in HIF-1α expression between the cell lines, blot intensities were analyzed using Image J. HEC1A/EMP2 cells significantly induced HIF-1α expression compared to HEC1A/V cells (Figure 5b; P=0.0008). Reduction in EMP2 in HEC1A/RIBO, also showed a significant reduction in HIF-1α expression (P=0.02).
HIF proteins have a number of important roles in cellular physiology that include the regulation of angiogenesis as well as metabolism.26, 27 To determine if the regulation of HIF-1α expression by EMP2 is restricted to VEGF, proteins involved with glycolysis were examined (Figure 5c). EMP2 expression directly correlated with glucose transporter-1 (GLUT1) expression, and significant differences were observed between HEC1A/EMP2 and HEC1A/sh911 (P=0.04). Whereas high EMP2 also appeared to slightly increase the expression of lactate dehydrogenase A, no significant differences were observed between the cell lines (Figure 5c).
We next focused on understanding the mechanism by which EMP2 regulated HIF-1α expression. As EMP2 has been shown to promote integrin-mediated FAK and Src activation,9, 28 the contribution of FAK/Src signaling to HIF-1α expression was determined. Using common inhibitors of AKT, PI3-kinase, EGFR and Src tyrosine kinases, HEC1A/EMP2 cells were treated with these agents while in a hypoxic chamber. As shown in Figure 5b, EMP2-induced overexpression of HIF-1α was reversed using Src inhibitors PP2 and dasatinib, respectively. Both erlotinib and Ly294002, a PI3-kinase inhibitor, also produced a similar effect, suggesting an overlap in signaling with EMP2. In contrast, AKTi did not alter HIF-1α expression in these cells (Figure 5d).
To validate the effects of FAK signaling on HIF-1α expression, HEC1A/EMP2 and HEC1A/V cells were transiently transfected with scrambled or FAK siRNA (Figure 5e). After 24 h in a hypoxic chamber, HIF-1α expression was determined. Reduction in FAK expression significantly diminished HIF-1α expression in both cell lines (Figure 5e, right). A 68±3% reduction in FAK expression decreased HIF-1α expression by 48±3% in HEC1A/EMP2 cells. A similar reduction was observed in HEC1A/V cells where decreasing FAK expression by 51±5% produced an 82±8% drop in HIF-1α expression.
EMP2 is a novel oncogene upregulated in a number of cancers in women. In endometrial cancer, for example, EMP2 expression promotes endometrial cancer growth in vivo,9 and to date, it is the only biomarker identified to predict endometrial cancer prognosis and survival.11, 14 Given its expression profile and importance in disease pathogenesis, we previously generated a recombinant antibody fragment (diabody) to EMP2, and have shown that it induces necrosis in vivo.15 Since then, we have generated an EMP2 IgG1 with similar in vitro and in vivo properties (Fu and Wadehra, submitted), and have started to characterize its mechanism of action in vitro and in vivo.
Using endometrial cancer cells, EMP2 IgG1 treatment significantly reduced tumor load with a net improvement in survival. Within tumors, significant necrosis was observed. To understand its mechanism of action, we generated cells with reduced EMP2 expression using ribozymes or specific shRNA constructs, which revealed a similar histology. In particular, severe necrosis was observed in tumors with reduced EMP2. Although we had previously observed increased cell death in vitro after exposure to antibodies that recognize EMP2, the necrotic response and the studies reported in this paper link EMP2 with control of VEGF expression through HIF-1α. Notably, HEC1A cells that were genetically modified for EMP2 expression showed a positive correlation between EMP2 levels and tumor vascularity. Cell supernatants from cells that were genetically modified for EMP2 expression showed a positive correlation between EMP2 levels, and endothelial cell migration and tube formation of two independent endothelial types under hypoxic conditions. Levels of VEGF and HIF-1α were concordant also with expression levels of EMP2, and blockade of EMP2 using an anti-EMP2 antibody showed a dose-dependent decrease in vascularization.
Whereas additional investigations will be needed to identify how EMP2 controls HIF-1α expression, its effects do not appear to be limited to angiogenesis. As HIF-1 also regulates metabolism,26 the significant alteration in GLUT1 expression suggests that EMP2 upregulation may have an adaptive role in promoting and establishing endometrial cancer tumorigenesis.Whereas it is known that several oncogenes stimulate angiogenesis,29 all of the studies presented here point to a significant effect on HIF-1α and VEGF through control of EMP2 expression, and suggest the mechanism for the clinical association of high EMP2 expression with aggressive, more advanced tumors.12, 14 Our results also suggest that EMP2 activates HIF-1α in a hypoxic environment through a FAK-Src-dependent mechanism. Although a similar trend in HUVEC migration and wound closure was observed under normoxic conditions, the differences were not statistically significant (data not shown). Under hypoxic conditions, the control of angiogenesis by EMP2 appears to be independent of AKT activation, suggesting that EMP2 and AKT regulate separate pathways. This is consistent with published reports that AKT signaling is neither required for HIF-1α expression nor stabilization under hypoxic conditions.30 Although AKT inhibitors did not suppress EMP2 mediated HIF-1α activation, erlotinib and Ly294002, the phosphatidylinositol 3-kinase (PI3K) inhibitor, were sufficient to inhibit its expression. This is not unexpected as EGFR neutralizing antibodies have been shown to have potent antitumor cytotoxic-like effects in vivo (where angiogenesis is required) but not in vitro (where it is not).23 This would also suggest that in endometrial cancer cells, similar to what has been observed in other tumor models, EGFR stimulates HIF-1α activation via a PI3K-mediated but AKT independent manner.31, 32 Is there overlap between EMP2 and EGFR signaling? We hypothesize that there is some overlap. Previous studies have shown that EMP2 promotes integrin expression and activation.33, 34 As both integrins and EGFR can signal through MAP kinase activation, we predict this may be a common thread between the two pathways.31, 35
The data presented here suggest that anti-EMP2 therapy in the disease has a combination of effects (direct toxicity and indirect regulation of VEGF) that supports its therapeutic potential. This is particularly important, given that the promise of anti-angiogenic agents has been incomplete.36 Initial clinical successes, prolonged overall and progression-free survival, using anti-VEGF antibody therapy in colorectal cancer prompted more widespread clinical use of these agents. However, these promising results were not replicated in multiple tumor types including metastatic breast cancer, resulting in withdrawal of FDA approval for its use in this tumor type. Indeed, some tumors escape VEGF inhibition through both hypoxia-dependent and hypoxia-independent manners. In addition, VEGF blockade may lead to proinflammatory molecules that might enhance tumor progression.37 Could a similar effect be observed with longer anti-EMP2 treatment? Although our results are promising, additional investigations are required to further to define the long-term consequences of anti-EMP2 treatment.
The human endometrial adenocarcinoma cell line HEC1A (HTB112, ATCC, Manassas, VA, USA) was cultured in McCoys media supplemented with 10% fetal calf serum at 37 °C in a humidified 5% CO2 incubator. Cell lines were used within 2 months after resuscitation of frozen aliquots, and were authenticated based on viability, recovery, growth, morphology and isoenzymology by the supplier. Stably transfected HEC1A cells containing a human EMP2-GFP fusion protein, control GFP or EMP2-specific ribozyme have been previously described.33, 38 Stably infected HEC1A cells containing a non-targeting shRNA control (HEC1A/shCtrl) or EMP2-specific shRNA (HEC1A/sh911) (911; TRCN0000322911) in pLKO.1-puro were generated as per manufacturer's instructions (Sigma-Aldrich, St Louis, MO, USA).
Human umbilical vein endothelial cells (HUVEC) from passage 2 were purchased from BD Biosciences (San Diego, CA, USA), and used between passages 3 and 7 for all experiments. Primary HAECs (gift from Dr J Berliner, UCLA) were also utilized. All endothelial cells were grown in complete MCDB-131 complete media (VEC Technologies, Renesselaer, NY, USA).
Ethical treatment of animals statement: This study was carried out in strict accordance with the recommendations in the Guide for the Care and Use of Laboratory Animals of the National Institutes of Health. The protocol was approved by the Animal Research Committee at the University of California, Los Angeles CA, USA. All efforts were made to minimize animal suffering.
Four- to six-week-old nude BALB/c female mice were obtained from Charles River Laboratories (Wilmington, MA, USA) and maintained at the University of California, Los Angeles, CA, USA. Animals were inoculated subcutaneously with 1 × 106 HEC1A/EMP2, HEC1A/V or HEC1A/RIBO cells into the right and left shoulder flanks, respectively. Tumors were measured using calipers, and the volume calculated with the formula: length × width2/2. Six mice were used per group. At day 30, tumors were excised, fixed in formalin, and then processed for hematoxylin and eosin staining by the Tissue Procurement Laboratory at UCLA or by Masson's trichrome stain (Dako, Carpinteria, CA, USA).
In some experiments, 1 × 106 HEC1A/EMP2 cells were suspended in 5% matrigel (BD Biosciences, Franklin Lakes, NJ, USA) and injected subcutaneously into the shoulder of female athymic mice. When tumors approached 4 mm2, systemic treatments with 10 mg/kg dose of anti-EMP2 IgG1 or control IgG (Sigma-Aldrich) were administered weekly via an intraperitoneal route. Tumor size was monitored, and mice euthanized once tumors approached 1.5 cm in diameter, mice appeared moribund or showed a 10% reduction in weight, or tumors became ulcerated. Tumors were isolated, fixed and processed for hematoxylin and eosin staining as previously described.14
Samples were analyzed to quantitate and identify tumor vasculature. Masson's trichrome staining was performed according to the manufacturer's instructions (Dako). Samples were deparaffinized and dehydrated in alcohol. In some experiments, after blocking in 1% normal goat serum, samples were incubated with 1:50 dilution of FITC-labeled L. esculentum lectin (1 mg/ml in 0.9% NaCl; Vector Laboratories, Burlingame, CA, USA). Samples were then counterstained with DAPI and mounted. To quantitate CD34 expression, samples were deparaffinized and then incubated at 95 °C for 20 min in 0.1 M citrate, pH 6.0. Rat anti-CD34 (Abcam, Cambridge, MA, USA) was used at a dilution of 1:25 as previously described39, followed by visualization using the Vector ABC kit (Vector Laboratories, Burlingame, CA, USA) according to the manufacturer's instructions. The numbers of CD34-positive blood vessels in six high-power fields ( × 200) were counted and averaged.
Capillary-like tube formation was performed as previously described.40 Briefly, coverslips were coated with reduced growth factor basement membrane (Geltrex; Invitrogen, Carlsbad, CA, USA) and incubated at 37 °C for 30 min to promote jelling. 5 × 105 HUVECs were resuspended in cultured media from HEC1A/EMP2, HEC1A/V or HEC1A/RIBO cells. Conditioned media was typically prepared as follows: cells were grown in a bag to mimic hypoxic conditions for up to 72 h or placed in a 0.5% hypoxic chamber (BioSpherix, Lacona, NY, USA) for up to 24 h. The cultured media was then collected and centrifuged to remove cell debris. In some experiments, HEC1A or HEC1A/EMP2 cells were treated with 100 μg/ml of the full-length EMP2 IgG1 for 24 h under hypoxic conditions for 12–15 h. In other experiments, recombinant human VEGF (Sigma-Aldrich) was used as an inducer of capillary tube formation from 0–50 ng/ml on HUVEC cells. After 18 h, cells were stained with calcein AM and analyzed using an Olympus BX51 light microscope. Tubes were counted using a 10 × objective connected to a DP72 digital camera. Three random fields were measured at each culture condition. Each experiment was repeated at least three times.
HUVEC and HAEC migration assays were conducted in Boyden chambers as previously reported (2). Conditioned media was prepared as described above. In some experiments, cultured supernatants from tumor cells were treated with bevacizumab (Genentech BioOncology, South San Francisco, CA, USA). Bevacizumab was obtained from the pharmacy at University of California, Davis, CA, USA. Each condition was assayed in triplicate wells. ‘Scratch' wound closure assays were performed by creating a confluent monolayer of HUVEC cells. Using the tip of a Pasteur pipet, a scratch was created. Conditioned media from HEC1A/EMP2, HEC1A/V or HEC1A/RIBO cells were added to the wells. Three random measurements for each of the three wounds were measured for each test condition. The experiment was repeated three times.
For RT-PCR analysis, total cellular RNAs were isolated using RNeasy mini kit (Qiagen, Valencia, CA, USA). In all conditions, 1 μg of total RNA was reversed transcribed using oligo(dT) primers and Moloney murine leukemia virus reverse transcriptase (Invitrogen). For VEGF amplification including all four splice variants, the PCR conditions and primers were utilized as previously described.41 Amplification of a GAPDH cDNA fragment was performed in a separate PCR reaction as described.42 PCR products were run on a 2% agarose gel and were visualized by ethidium bromide staining.
In some experiments, cells were transiently transfected with FAK siRNA or a scrambled control as previously described.8 Briefly, HEC1A/EMP2 or HEC1A/V cells were transiently transfected with 75 pmol FAK siRNA (L-003164-00, ThermoScientific, Lafayette, CO, USA) or a scrambled control (D-001206-13-05, ThermoScientific). After 6 h, cells were placed in a 0.5% hypoxic chamber for 24 h and then processed for western blot analysis as detailed below.
Cells were lysed in Laemmli buffer. Proteins were separated by SDS-PAGE, transferred to a nitrocellulose membrane (GE Healthcare Biosciences, Piscataway, NJ, USA), and stained with Ponceau S (Sigma-Aldrich) to determine transfer efficiency. Membranes were blocked with 10% low-fat milk in PBS containing 0.1% Tween 20 and probed with EMP2 antisera (1:1000), anti-VEGF (Santa Cruz Biotech, Santa Cruz, CA, USA), anti-HIF-1α (1:800; BD Biosciences), anti-PPAR-γ (Santa Cruz Biotech), anti-416 p-Src (Cell Signaling, Danvers, MA, USA), anti-p-AKT (Cell Signaling), anti-576/577p-FAK (1:500; BD Biosciences) or β-actin (Sigma-Aldrich). Protein bands were visualized using a horseradish peroxidase-labeled secondary antibody (BD Biosciences; Southern Biotechnology Associates, Birmingham, AL, USA) followed by chemiluminescence (ECL; GE Healthcare Biosciences). Band intensities were quantified using the NIH program Image J as above. To account for loading variability β-actin was used to normalize each sample. At least three independent experiments were performed and, where indicated, the results were evaluated for statistical significance using a Student's t-test (unpaired, one-tail). A level of P<0.05 was considered to be statistically significant.
In some experiments, inhibitors were added to determine the contribution of specific pathways to HIF-1α expression. HEC1A/EMP2 cells were treated with 10 μM of the FAK-Src small molecule inhibitor PP2 or the small molecule control PP3,8 5 μM of Akt inhibitor VIII (Barnett et al.16 Calbiochem, San Diego, CA, USA), 50 μM of the PI3 kinase inhibitor Ly294002 (Cell Signaling), the EGFR inhibitor Erlotinib (Wang et al.17 10 μM, Genentech) or the Src family tyrosine kinase inhibitor Dasatinib (Lu et al.43 10 μM, Bristol-Myers Squibb). Efficacy of the inhibitors was tested at the manufacturer's recommended dosage, and potential toxicity was measured using trypan-blue exclusion. Samples were harvested and probed by SDS–PAGE/western blot analysis as above.
We are grateful to Dr Heather Christofk and her laboratory for use of the hypoxic chamber, and thankful to Dr Judith Berliner and Dr Sangderk Lee for providing HAEC cells. This work was generously supported by the Early Detection Research Network NCI CA-86366 (LG), NIH grants CA16042 (JB), CA131756 (MW), CA163971 (MW), the Stein Oppenheimer Award (MW) and Richard and Barbara Braun fund.
This work has been funded by the NIH. MW, JB and LKG are inventors on the University of California patents related to the EMP2 IgG1 antibody and diabody, and hold equity in a company related to EMP2. MK, MF, PD, AC and LG declare no potential conflicts of interest.
|Travasso RDM,Corvera Poiré E,Castro M,Rodrguez-Manzaneque JC,Hernández-Machado A. Tumor angiogenesis and vascular patterning: a mathematical modelPLoS OneYear: 20116e1998921637756|
|Park JE,Keller HA,Ferrara N. The vascular endothelial growth factor isoforms (VEGF): differential deposition into the subepithelial extracellular matrix and bioactivity of extracellular matrix-bound VEGFMol Biol CellYear: 19934131713268167412|
|Ferrara N. VEGF and the quest for tumour angiogenesis factorsNat Rev CancerYear: 2002279580312360282|
|Ferrara N,Hillan KJ,Gerber H-P,Novotny W. Discovery and development of bevacizumab, an anti-VEGF antibody for treating cancerNat Rev Drug DiscovYear: 2004339140015136787|
|Cébe-Suarez S,Zehnder-Fjällman A,Ballmer-Hofer K. The role of VEGF receptors in angiogenesis; complex partnershipsCell Mol Life SciYear: 20066360161516465447|
|Tang N,Wang L,Esko J,Giordano FJ,Huang Y,Gerber H-P,et al. Loss of HIF-1[alpha] in endothelial cells disrupts a hypoxia-driven VEGF autocrine loop necessary for tumorigenesisCancer CellYear: 2004648549515542432|
|Inoue M,Hager JH,Ferrara N,Gerber H-P,Hanahan D. VEGF-A has a critical, nonredundant role in angiogenic switching and pancreatic 2 cell carcinogenesisCancer CellYear: 2002119320212086877|
|Morales S,Mareninov S,Prasad P,Wadehra M,Braun J,Gordon LK. Collagen gel contraction by ARPE-19 is mediated by a FAK-Src dependent pathwayExp Eye ResYear: 20078579079817915217|
|Fu M,Rao R,Sudhakar D,Hogue CP,Rutta Z,Morales S,et al. Epithelial membrane protein-2 promotes endometrial tumor formation through activation of FAK and SrcPLoS OneYear: 20116e1994521637765|
|Morales SA,Mareninov S,Coulam P,Wadehra M,Goodglick L,Braun J,et al. Functional consequences of interactions between FAK and epithelial membrane protein 2 (EMP2)Invest Ophthalmol Vis SciYear: 2009504949495619494199|
|Habeeb O,Goodglick L,Soslow RA,Rao RG,Gordon LK,Schirripa O,et al. Epithelial membrane protein-2 expression is an early predictor of endometrial cancer developmentCancerYear: 20101164718472620578181|
|Fu M,Maresh EL,Soslow RA,Alavi M,Mah V,Zhou Q,et al. Epithelial membrane protein-2 is a novel therapeutic target in ovarian cancerClin Cancer ResYear: 2010163954396320670949|
|Freije WA,Castro-Vargas FE,Fang Z,Horvath S,Cloughesy T,Liau LM,et al. Gene expression profiling of gliomas strongly predicts survivalCancer ResYear: 2004646503651015374961|
|Wadehra M,Natarajan S,Seligson DB,Williams CJ,Hummer AJ,Hedvat C,et al. Expression of epithelial membrane protein-2 is associated with endometrial adenocarcinoma of unfavorable outcomeCancerYear: 2006107909816736513|
|Shimazaki K,Lepin EJ,Wei B,Nagy AK,Coulam CP,Mareninov S,et al. Diabodies targeting epithelial membrane protein 2 reduce tumorigenicity of human endometrial cancer cell linesClin Cancer ResYear: 2008147367737719010852|
|Barnett SF,Defeo-Jones D,Fu S,Hancock PJ,Haskell KM,Jones RE,et al. Identification and characterization of pleckstrin-homology-domain-dependent and isoenzyme-specific Akt inhibitorsBiochem JYear: 200538539940815456405|
|Wang MY,Lu KV,Zhu S,Dia EQ,Vivanco I,Shackleford GM,et al. Mammalian target of rapamycin inhibition promotes response to epidermal growth factor receptor kinase inhibitors in PTEN-deficient and PTEN-intact glioblastoma cellsCancer ResYear: 2006667864786916912159|
|Kadenhe-Chiweshe A,Papa J,McCrudden KW,Frischer J,Bae J-O,Huang J,et al. Sustained VEGF blockade results in microenvironmental sequestration of VEGF by tumors and persistent VEGF receptor-2 activationMol Cancer ResYear: 200861918234958|
|Kilarski WW,Samolov B,Petersson L,Kvanta A,Gerwins P. Biomechanical regulation of blood vessel growth during tissue vascularizationNat MedYear: 20091565766419483693|
|Mancuso MR,Davis R,Norberg SM,O'Brien S,Sennino B,Nakahara T,et al. Rapid vascular regrowth in tumors after reversal of VEGF inhibitionJ Clin InvestYear: 20061162610262117016557|
|Wang B,Xiao Y,Ding B-B,Zhang N,Yuan X-b,Gui L,et al. Induction of tumor angiogenesis by Slit-Robo signaling and inhibition of cancer growth by blocking Robo activityCancer CellYear: 20034192912892710|
|Kerbel RS. Tumor AngiogenesisN Engl J MedYear: 20083582039204918463380|
|Okada F,Rak JW,Croix BS,Lieubeau B,Kaya M,Roncari L,et al. Impact of oncogenes in tumor angiogenesis: Mutant K-ras up-regulation of vascular endothelial growth factor/vascular permeability factor is necessary, but not sufficient for tumorigenicity of human colorectal carcinoma cellsProc Natl Aca SciYear: 19989536093614|
|Robinson CJ,Stringer SE. The splice variants of vascular endothelial growth factor (VEGF) and their receptorsJ Cell SciYear: 200111485386511181169|
|Bates DO,MacMillan PP,Manjaly JG,Qiu Y,Hudson SJ,Bevan HS. The endogenous anti-angiogenic family of splice variants of VEGF, VEGFxxxb, are down-regulated in pre-eclamptic placentae at termClin Sci (London)Year: 200611057558516451124|
|Semenza GreggL. Hypoxia-inducible factors in physiology and medicineCellYear: 201214839940822304911|
|Seton-Rogers S. Hypoxia: HIF switchNat Rev CancerYear: 20111139139121606940|
|Morales SA,Mareninov S,Wadehra M,Zhang L,Goodglick L,Braun J,et al. FAK activation and the role of epithelial membrane protein 2 (EMP2) in collagen gel contractionInvest Ophthalmol Vis SciYear: 20095046246918469192|
|Dvorak HF. Vascular permeability factor/vascular endothelial growth factor: a critical cytokine in tumor angiogenesis and a potential target for diagnosis and therapyJ Clin OncolYear: 2002204368438012409337|
|Arsham AM,Plas DR,Thompson CB,Simon MC. Phosphatidylinositol 3-kinase/Akt signaling is neither required for hypoxic stabilization of hif-1α nor sufficient for HIF-1-dependent target gene transcriptionJ Biol ChemYear: 2002277151621517011859074|
|Mahimainathan L,Ghosh-Choudhury N,Venkatesan BA,Danda RS,Choudhury GG. EGF stimulates mesangial cell mitogenesis via PI3-kinase-mediated MAPK-dependent and AKT kinase-independent manner: involvement of c-fos and p27Kip1Am JPhysiol–Renal PhysiolYear: 2005289F72F8215701816|
|Vivanco I,Sawyers CL. The phosphatidylinositol 3-Kinase AKT pathway in human cancerNat Rev CancerYear: 2002248950112094235|
|Wadehra M,Forbes A,Pushkarna N,Goodglick L,Gordon LK,Williams CJ,et al. Epithelial membrane protein-2 regulates surface expression of alphavbeta3 integrin in the endometriumDev BiolYear: 200528733634516216233|
|Wadehra M,Iyer R,Goodglick L,Braun J. The tetraspan protein epithelial membrane protein-2 interacts with beta1 integrins and regulates adhesionJ Biol ChemYear: 2002277410944110012189152|
|Aplin AE,Short SM,Juliano RL. Anchorage-dependent regulation of the mitogen-activated protein kinase cascade by growth factors is supported by a variety of integrin alpha chainsJ Biol ChemYear: 1999274312233122810531317|
|Leite de Oliveira R,Hamm A,Mazzone M. Growing tumor vessels: more than one way to skin a cat—Implications for angiogenesis targeted cancer therapiesMol Aspects MedYear: 201132718721540050|
|Zagzag D,Lukyanov Y,Lan L,Ali MA,Esencay M,Mendez O,et al. Hypoxia-inducible factor 1 and VEGF upregulate CXCR4 in glioblastoma: implications for angiogenesis and glioma cell invasionLab InvestYear: 2006861221123217075581|
|Wadehra M,Dayal M,Mainigi M,Ord T,Iyer R,Braun J,et al. Knockdown of the tetraspan protein epithelial membrane protein-2 inhibits implantation in the mouseDev BiolYear: 200629243044116487956|
|Ogawa K,Pasqualini R,Lindberg RA,Kain R,Freeman AL,Pasquale EB. The ephrin-A1 ligand and its receptor, EphA2, are expressed during tumor neovascularizationOncogeneYear: 2000196043605211146556|
|Arnaoutova I,Kleinman HK. In vitro angiogenesis: endothelial cell tube formation on gelled basement membrane extractNat ProtocYear: 2010562863520224563|
|Merdzhanova G,Gout S,Keramidas M,Edmond V,Coll JL,Brambilla C,et al. The transcription factor E2F1 and the SR protein SC35 control the ratio of pro-angiogenic versus antiangiogenic isoforms of vascular endothelial growth factor-A to inhibit neovascularization in vivoOncogeneYear: 2010295392540320639906|
|Wadehra M,Braun J,Goodglick L. One step RT-PCR for screening microdissected tissueBiotechniquesYear: 20023224224711848395|
|Lu KV,Zhu S,Cvrljevic A,Huang TT,Sarkaria S,Ahkavan D,et al. Fyn and SRC are effectors of oncogenic epidermal growth factor receptor signaling in glioblastoma patientsCancer ResYear: 2009696889689819690143|
Keywords: EMP2, VEGF, neoangiogenesis.
Previous Document: Integrative molecular and functional profiling of ERBB2-amplified breast cancers identifies new gene...
Next Document: Methylation-mediated silencing of the miR-124 genes facilitates pancreatic cancer progression and me...